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It is very likely that the same will apply to HIV 
prevention in women. 
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Crucial but understudied: incentives in HIV research
In this issue of The Lancet HIV, Katherine Kranzer 
and colleagues1 report that economic incentives for 
caregivers in Zimbabwe increased uptake of HIV testing 
and counselling by children aged 8–17 years compared 
with caregivers with no financial incentive. HIV 
testing of groups that are hard to reach is a formidable 
challenge worldwide, and innovative strategies to reach 
adolescents in particular are crucial to reaching UNAIDS’ 
90-90-90 goals.2
These results provide further evidence of the 
importance of incentives to motivate research 
participation (in this case, receiving an HIV test) as part 
of a large community-based household survey. Still, 
the question remains as to what incentive amounts are 
appropriate, inadequate, or excessive.3 Although the 
issue of undue inducement might be less problematic 
in routine care (HIV testing) versus early phase, 
riskier HIV-cure research, the issue is the same: the 
process leading to the study’s incentive amounts are 
unknown. For example, were community members or 
the participant population consulted on the incentive 
decision? The volunteer community wants to have 
a say on the type and amount of financial incentives 
in HIV research.4 Engagement with participants on 
the topic of payment is just one of the many types of 
consultation that should occur in research.5 In short, 
this includes engaging the participant community 
beforehand, collaboratively pursuing research ideas that 
address a topic that is important to the community, 
using methods that are acceptable to community, and 
involving community input and leadership in every 
phase of the project.
In the present study, the fixed US$2 incentive is 
about 2% of the average monthly income ($100) of 
study households, meaning that $2 approaches the 
daily household income. The $10 lottery is about 10% 
of the monthly income. Although payment cannot be 
considered a benefit from the regulatory perspective, 
study participants nonetheless often consider financial 
incentives as a benefit received in exchange for study 
participation.6 This might be even more salient in 
resource-limited settings.
Another issue worth further exploration is the 
sustainability of economic incentives for HIV testing in 
a non-research context. Payment is a strong motivator 
for caregivers to have their children tested for HIV, but 
it remains to be seen whether the approach will work in 
a programmatic setting. Additionally, payment for HIV 
testing in a research study could generate unrealistic 
expectations about receiving such payments when 
the study ends, potentially leading to refusal of non-
compensating HIV testing. In fact, some researchers7 
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have shown that incentives might not be able to 
overcome important barriers to care.
A third issue is the use of payments to incentivise 
caregivers to get their children tested for HIV. Although 
payment was not concealed from the children, whether 
the children received any portion of the payment is 
unknown, although it was the children who received the 
HIV test. This approach was entirely appropriate in this 
context, but raises unique ethical concerns with respect 
to providing financial incentives to children, including 
payment possibly unduly influencing their decision 
making or that of their parents.8 However, if a nominal 
amount of money can help get hard-to-reach people 
tested for HIV and treated if indicated, there could be 
large, long-term savings in medical costs by treating 
those with early HIV disease sooner rather than later and 
by adverting onward transmission if these patients are 
virally suppressed.9
Use of financial incentives to support participation 
in HIV research is standard practice, and Kranzer and 
colleagues present a compelling case for incentivised 
programmatic HIV testing. Additionally, recent 
evidence10 supports the use of financial incentives 
to increase viral suppression and clinic attendance 
in people living with HIV and to improve treatment 
adherence in patients with substance use disorders.11 
These are good and desired outcomes for patients. 
Nonetheless, the ethical issues of incentive use in this 
and other types of HIV research, especially research with 
greater risks such as HIV cure research, warrant deeper 
exploration.
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Preventing tuberculosis-related death in children with HIV
In 2015 there were an estimated 1 million new cases of 
tuberculosis in children.1 During 2010, it was estimated 
that in some sub-Saharan countries with high HIV 
prevalence, more than 20% of tuberculosis cases occurred 
in children.2 In a meta-analysis, the pooled case fatality 
ratio in HIV-infected children receiving tuberculosis 
treatment but not antiretroviral therapy (ART) was 
14·3%, compared to 3·4% in individuals receiving both 
tuberculosis treatment and ART.3 Marcy and colleagues4 
describe high mortality (19%) in ART-naive HIV-
infected children presenting for care with suspected 
intrathoracic tuberculosis. The authors categorised 
children by use of consensus definitions, which included 
clinical, microbiological, and radiological criteria, as 
having confirmed, unconfirmed, or unlikely tuberculosis. 
Tuberculosis treatment of children with confirmed or 
unconfirmed disease was associated with substantially 
lower mortality (p<0·0001). Early ART was similarly 
associated with reduced mortality (hazard ratio=0·08).4
This study was done in two African and two Asian 
countries, and few children (<4%) were lost to follow-
up.4 However, as this was an observational study and 
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